Comparative Pharmacology
Head-to-head clinical analysis: HYDROFLUMETHIAZIDE versus NAQUA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROFLUMETHIAZIDE versus NAQUA.
HYDROFLUMETHIAZIDE vs NAQUA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroflumethiazide is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and promoting diuresis. It also causes vasodilation by reducing peripheral vascular resistance.
Inhibition of sodium-chloride symporter (NCC) in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and promoting diuresis.
Oral: 25-50 mg once daily; may increase to 100 mg/day in divided doses if needed.
Oral: 5-10 mg once daily, preferably in the morning. Maximum dose 20 mg/day.
None Documented
None Documented
Terminal elimination half-life of 6-9 hours in patients with normal renal function; clinically, this supports once-daily dosing in hypertension but may require twice-daily dosing in some patients with impaired renal function
Clinical Note
moderateHydroflumethiazide + Digoxin
"The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Digoxin."
Clinical Note
moderateHydroflumethiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Digitoxin."
Clinical Note
moderateHydroflumethiazide + Deslanoside
"The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Deslanoside."
Clinical Note
moderateTerminal elimination half-life is 6-12 hours; prolonged in renal impairment (up to 20-30 hours) or heart failure due to reduced renal perfusion.
Primarily renal (approximately 85% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%)
Primarily renal elimination; approximately 60-80% excreted unchanged in urine via tubular secretion; minor biliary/fecal excretion (<10%).
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic
Hydroflumethiazide + Acetyldigitoxin
"The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Acetyldigitoxin."